Heart Failure

A new analysis of more than 125,000 found no differences in mortality or MACE based on type of insulin used.

New data suggests sacubitril/valsartan could reduce risk of hospitalization and mortality in HFrEF patients when compared with ACEs/ARBs.

A new review in the Journal of the American College of Cardiology is highlighting the impact of marijuana use on heart health.

New research suggests Abbott's HeartMate 3 could revolutionize preimplantation strategy by eliminating use of categories based on transplant eligibility.

Less than 1 in 4 eligible Medicare patients attend a cardiac rehabilitation program and, among participants, adherence to programs remains an issue.

An analysis of more than 9000 patients found incident heart disease was associated with an increased risk of developing kidney failure later in life.

A recent study found a lower blood pressure target in older adults could reduce risk of cardiovascular events and death, but could negatively impact kidney function.

Abbot announced early Tuesday morning that the US FDA has granted approval for the HeartMate 3 device to be implanted via a lateral thoracotomy for patients with advanced heart failure.

A study from investigators at UCLA has identified a biomarker investigators suggest can help identify stable heart failure patients at an increased risk of death within the next 3 years.

Increased levels of pyrethroid insecticide exposure was linked to increased in all-cause mortality, as well as increases in mortality from cancer and cardiovascular disease in a recent study from the University of Iowa.

A recent study from the Mayo Clinic of Rochester, MN is suggested diabetes mellitus is an independent risk factor for the development of heart failure.

How the two critical specialties become better bridged at medical meetings?

How women who undergo menopause before age 40 may be at a greater risk of heart disease.

How technology, innovation, and preventive care drove the last 10 years of improved public heart health.

A discussion on why heart failure rates have climbed over the past decade while research indicates rates of cardiovascular disease, as a whole, have begun to decline.

Evaluating the impact of DAPA-HF and other recent data that have changed the way cardiologists view the potential uses of SGLT2 inhibitors in patients with or without diabetes.

A new analysis from the University of Minnesota has found many patients with and without an indication for regular low dose aspirin use are under or overusing the medication.

Why US patients are now in absolute need of proven measures to lessen their risk of cardiovascular burden.

What more needs to be learned about the link between the 2 diseases?

A conversation with Deepak Bhatt, MD, MPH, discussing the most impactful advances in cardiology in 2019 and what he sees as the most important advances in the past decade as 2019 comes to a close.

How preventive care strategy adherence could bolster heart disease risk reduction in entire families.

A fourth-year cardiology medical student shares his perspectives from the audience at the American Heart Association Scientific Sessions.

New empagliflozin data assesses the SGLT-2 inhibitor versus GLP-1 agonists and DPP-4 inhibitors for patients with heart failure.

The adult heart failure study is the first of its kind: a completely decentralized, indication-seeking clinical trial.

George Bakris, MD, discusses how nephrologists can work with other specialists and what the highlight of Kidney Week was.